![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Genetron Health Gets CE Mark for its Seq-MRD, Residual Cancer Detection Kit
Genetron Health Gets CE Mark for its Seq-MRD, Residual Cancer Detection Kit
Beijing, China-based Genetron Health has received CE mark certification for its Seq-MRD B-lymphocyte minimal residual disease detection kit.
The assay tests bone marrow samples collected from patients with B-lymphpocytic leukemia and multiple myeloma before and after treatment.
This approach can detect minimal residual disease and provide a reference for follow-up treatment of cancer survivors, the company said.
Genetron, which specializes in molecular profiling tests, early cancer screening products and companion diagnostics, said it believes the Seq-MRD gene sequencing technology has many potential applications.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct